<i>Lacticaseibacillus rhamnosus</i> LM1019 Enhances Natural Killer Cell Activity in Defined Adult Subsets: A Double-Blind, Placebo-Controlled Trial
Probiotics offer a non-pharmacological approach to support immune function, yet clinical evidence for strain-specific benefits remains limited. We conducted an 8-week, randomized, double-blind, placebo-controlled trial of <i>Lacticaseibacillus rhamnosus</i> LM1019 in 121 generally health...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/15/7/1002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Probiotics offer a non-pharmacological approach to support immune function, yet clinical evidence for strain-specific benefits remains limited. We conducted an 8-week, randomized, double-blind, placebo-controlled trial of <i>Lacticaseibacillus rhamnosus</i> LM1019 in 121 generally healthy adults. Both the active and placebo arms produced comparable within-group increases in natural killer (NK) cell cytotoxicity and modest, non-differential declines in circulating cytokines; safety and tolerability were excellent, with mild adverse events evenly distributed. In a post-hoc subgroup defined by age ≥ 40 years, baseline white blood cell count ≥ 5.0 × 10<sup>3</sup>/µL, and LDL cholesterol < 130 mg/dL, the probiotic arm demonstrated statistically significant enhancements in NK activity (<i>p</i> = 0.021–0.008 across all effector-to-target ratios), whereas no change was observed in the placebo group. These findings suggest that this intervention may selectively boost NK-mediated immunity in individuals with preserved baseline immune and lipid profiles. Future larger trials using phenotype-driven enrollment and controlled dietary intake are warranted to confirm and extend these results. |
|---|---|
| ISSN: | 2075-1729 |